ArticleCurrent oncology (Toronto, Ont.)2016
Cost trajectories for cancer patients.
Article in Current oncology (Toronto, Ont.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study.PloS one · 2018Trial
- Associations between clinical pathway concordance, cost, and survival outcomes for stage II colon cancer: a population-based study.International journal for quality in health care : journal of the International Society for Quality in Health Care · 2023Article
- The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics.Journal of cancer survivorship : research and practice · 2022Article
- Coordination Models for Cancer Care in Low- and Middle-Income Countries: A Scoping Review.International journal of environmental research and public health · 2022Article
- Optimal Care Pathways for People with Lung Cancer- a Scoping Review of the Literature.International journal of integrated care · 2020Article
- The generation of two specific cancer costing algorithms using Ontario administrative databases.Current oncology (Toronto, Ont.) · 2019Article
- Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.The oncologist · 2017Article
- Integrated Care Planning for Cancer Patients: A Scoping Review.International journal of integrated care · 2017Article
- Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2017Observational
- Primary care physician use across the breast cancer care continuum: CanIMPACT study using Canadian administrative data.Canadian family physician Medecin de famille canadien · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealth care spending is known to be highly skewed, with a small subset of the population consuming a disproportionate amount of health care resources. Patients with cancer are high-cost users because of high incremental health care costs for treatment and the growing prevalence of cancer. The objectives of the present study included characterizing cancer-patient trajectories by cost, and identifying the patient and health system characteristics associated with high health system costs after cancer treatment.
methodsThis retrospective cohort study identified Ontario adults newly diagnosed with cancer between 1 April 2009 and 30 September 2010. Costs of health care use before, during, and after cancer episodes were used to develop trajectories of care. Descriptive analyses examined differences between the trajectories in terms of clinical and health system characteristics, and a logistic regression approach identified predictors of being a high-cost user after a cancer episode.
resultsTen trajectories were developed based on whether patients were high- or low-cost users before and after their cancer episode. The most common trajectory represented patients who were low-cost in the year before cancer, survived treatment, and continued to be low-cost in the year after cancer (31.4%); stage ii cancer of the male genital system was the most common diagnosis within that trajectory. Regression analyses identified increases in age and in multimorbidity and low continuity of care as the strongest predictors of high-cost status after cancer.
conclusionsFindings highlight an opportunity to proactively identify patients who might transition to high-cost status after cancer treatment and to remediate that transition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.